PhD researcher focused on inherited retinal diseases (IRDs) with experience spanning CRISPR-based gene editing, protein engineering, and antisense oligonucleotide (ASO) therapeutics. My work centers on overcoming delivery and target limitations in genetic medicine, including engineering a novel Cas variant and developing gene-agnostic ASO strategies for retinal degeneration. Beyond the bench, I’ve secured early project funding, built experimental pipelines, and engaged in venture creation through Nucleate. I’m driven to translate first-principles scientific insights into scalable therapeutic platforms, with a long-term goal of founding companies that address currently untreatable diseases.